Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Current prevention strategies in patients with recurrence of kidney stones show especially in
high-risk patients a diversely and in the long-term not successful outcome in a sustainable
number of cases. Recent studies have revealed that Dapagliflozin has the potential to
decrease risk and incidence of urolithiasis events especially in patients suffering from
Diabetes. The investigators propose that Dapagliflozin has the potential to increase the
metabolic situation of hyperoxaluric patients with recurrence of urolithiasis. The
investigators therefore test whether Dapagliflozin can decrease the oxalate excretion
compared to the current strategy with Hydrochlorothiazide. The study may open up a new way of
preventing urolithiasis in patients with high-risk of recurring urolithiasis.